Mersana Therapeutics Q2 2024 GAAP EPS $(0.20) Misses $(0.17) Estimate, Sales $2.293M Miss $8.722M Estimate
Author: Benzinga Newsdesk | August 13, 2024 07:03am
Mersana Therapeutics (NASDAQ:
MRSN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 17.65 percent. The company reported quarterly sales of $2.293 million which missed the analyst consensus estimate of $8.722 million by 73.71 percent. This is a 78.48 percent decrease over sales of $10.654 million the same period last year.
Posted In: MRSN